Isodiol International Inc (OTCMKTS: ISOLF) has been moving steadily up the charts in recent days on a significant surge in volume. The stock has a long history of big moves skyrocketing at the end of last year.
On January 11 Isodiol announced its BOD is re-examining the Company’s stock commitments for 2019 and making efforts to curb dilution and enhance shareholder value. The first of these efforts is the mutual termination of the Company’s license agreement with Level Brands Inc. for the kathy ireland® brand, which was effective as of January 7, 2019. Pursuant to the termination, the Company will retain the ability to sell products bearing the kathy ireland® brand through June 2019.
Isodiol International Inc (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) is a growth through acquisition story; Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its consumer products portfolio and aggressively continue international expansion into Latin America, Asia, and Europe.
Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, as was announced on April 26, 2018.
Isodial is seeing significant growth; the Company recently reported first quarter revenue of $9.2 million, representing an approximate 240% increase over the quarter ended June 30, 2017 and an approximate 70% increase over revenues of $5.4 million in the fourth quarter of fiscal 2018.
2018 has been a big year for Isodiol; they received government Approval from United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for Pure, Natural CBD as an Active Pharmaceutical Ingredient (API) They Completed the Acquisition of KURE Corp and also announced KURE expansion plans.
In May they acquired a turn-key brewing system, including a 7-bbl brewhouse, four 15-bbl fermentation tanks, a 30-bbl fermentation tank, a 15-bbl brite tank, and a 30-bbl brite tank, which is expected to yield between 1,500 and 2,000 bbls of production per year. In addition, IsoBev acquired a 12-ounce bottling line and a 22-ounce bottling line, which could yield over 600,000 12-oz bottles and 25,000 12-oz bottle cases per year.
To Find out the inside Scoop on Isodiol Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
In November Isodiol announces its financial and operational results for the second quarter of fiscal 2019, ended September 30, 2018. The company reported total Revenue of $8,030,825 with gross profit of $4,317,612.
CEO of Isodiol, Marcos Agramont stated “In anticipation of the US Farm bill being finalized,1 and with the possibility of an increase in demand for consumer packaged goods (CPG), the Company scaled back bulk raw ingredient CBD sales in an effort to increase production and inventory of CPG for 2019. While this has impacted our Q2 revenues, the Company believes this move was necessary for long-term, sustainable growth.”
In December Isodiol entered into a binding letter agreement for the acquisition of Food Labs, Inc. and strategic investor relationship with Toba Capital LLC. The transaction for Food Labs is valued at US$12 million, which includes US$5 million cash on its balance sheet, and also brings the appointment of a new Chief Executive Officer and Chairman of the Board of Directors of Isodiol. Food Labs is a brand-focused innovator of hemp- and cannabis-based consumer products with a flagship line of full spectrum, hemp-oil based health and wellness products. The Food Labs management team has extensive experience bringing consumer products to mass retail, including in the ready-to-drink beverage market. Leading the Food Labs team is Michael Cancelleri who also will become Chief Executive Officer and Chairman of the Board of Directors of Isodiol upon closing the transaction.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $53 million market valuation Isodiol has $3.2 million in the treasury, $22 million in current assets and significant debt with $63 million in current liabilities. Isodiol is an exciting Company that has seen explosive growth through acquisition recently reported Q2 revenue of $8,030,825. Isodiol was recently featured in mainstream press when the company was included as a show segment on the national PBS series “American Health Journal – Innovations in Medicine. Isodiol also recently entered into an agreement with Powerhouse Gym to be the preferred vendor of CBD performance products offered to its gym members. We will be updating on Isodiol when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with Isodiol.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in Isodiol either long or short and we have not been compensated for this article.